Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in adolescents with ADHD and cannabis abuse
NCT00687609Phase 4Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Primary endpoint: ADHD Rating Scale-IV-Parent Version Total Score at 12 weeks. Started Sep 2008; status: terminated.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00687609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687609.